阿利西尤单抗联合阿托伐他汀治疗冠心病合并高脂血症的价值研究

Study on the Value of Alirocumab Combined with Atorvastatin in the Treatment of Coronary Heart Disease Combined with Hyperlipidemia

目的 探讨阿利西尤单抗联合阿托伐他汀在冠状动脉粥样硬化性心脏病(以下简称冠心病)合并高脂血症中的治疗效果。方法 前瞻性随机选取山东济宁医学院附属高唐县人民医院于2021年12月—2023年12月收治的100例冠心病合并高脂血症患者为研究对象,利用随机数表法分成两组,各50例。对照组接受阿托伐他汀治疗,观察组接受阿托伐他汀+阿利西尤单抗治疗。比较两组的治疗效果、血脂指标及心功能指标。结果 观察组治疗总有效率为98.00%,高于对照组的84.00%,差异有统计学意义(χ^(2)=4.396,P<0.05)。治疗前,两组的血脂指标及心功能指标比较,差异无统计学意义(P均>0.05);治疗后,观察组的总胆固醇、甘油三酯、低密度脂蛋白胆固醇、左心室收缩末期内径及左心室舒张末期内径低于对照组,高密度脂蛋白胆固醇、左室射血分数高于对照组,差异有统计学意义(P均<0.05)。结论 阿利西尤单抗联合阿托伐他汀治疗冠心病合并高脂血症的效果更为显著,可改善患者高血脂症状,并促进心功能的恢复。

Objective To investigate the therapeutic effect of alirocumab combined with atorvastatin in coronary atherosclerotic heart disease(hereinafter referred to as coronary heart disease) complicated with hyperlipidemia.Methods 100 patients with coronary heart disease combined with hyperlipidemia admitted to Gaotang County People's Hospital Affiliated to Jining Medical University from December 2021 to December 2023 were prospective randomly selected as the study subjects,and they were divided into two groups of 50 cases each by using the method of randomized number table.The control group received atorvastatin treatment,and the observation group received atorvastatin + alirocumab treatment.Compare the therapeutic effect,blood lipid index and cardiac function index of the two groups.Results The total treatment efficiency of the observation group was 98.00%,higher than that of the control group(84.00%),the difference was statistically significant(χ~2=4.396,P<0.05).Before treatment,the difference between the lipid indexes and cardiac function indexes of the two groups was not statistically significant(both P>0.05);after treatment,total cholesterol,triglyceride,low-density lipoprotein cholesterol,left ventricular end-systolic internal diameter and left ventricular end-diastolic internal diameter of the observation group were lower than those of the control group,and high-density lipoprotein cholesterol and left ventricular ejection fraction were higher than those of the control group,and the differences were statistically significant(all P<0.05).Conclusion The effect of alirocumab combined with atorvastatin in the treatment of coronary heart disease combined with hyperlipidemia is more significant,which can improve the patients' hyperlipidemic symptoms and promote the recovery of cardiac function.